Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of PEGylated cixutumumab peptide in dialysis patients with renal anemia
CTR20150680Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of cixutumumab in anemia of chronic kidney disease, sponsored by Hengrui Therapeutics. Started May 2021; status: completed.
02
Drugs
cixutumumab
03
Conditions
anemia of chronic kidney disease
Beyond the preview
Go deeper on CTR20150680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150680.